Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Empowering Pharmaceutical Companies in Chronic Disease Research and Identifying Unmet Needs says Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

26 Sep, 2023, 07:35 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Sept. 26, 2023 /PRNewswire/ -- Chronic diseases are long term ailments that progress over time. They are non-communicable in nature and can lead to severe health complications if left undetected and untreated. Chronic disease prevalence has been increasing dramatically across the globe. Unhealthy lifestyle choices, rise in the geriatric populace, environmental degradation, genetic issues, and inadequate access to quality healthcare services are some of the major factors leading to the onset of long term illness in individuals.

There is a wide range of chronic diseases affecting millions of people worldwide. Such ailments might start developing at an early age with intended affects in later years. Effective management of such ailments involve early diagnosis, accurate medical intervention, lifestyle changes, and constant monitoring, among others. Healthcare professionals including researchers and physicians along with pharma leaders are constantly involve in R&D activities with an aim to find effective diagnostic and treatment solutions for the same.  World Health Organization's chronic disease statistics 2023 denotes that long terms ailments account for 41% million deaths each year. This rate is projected to soar in the coming years.

Disease Landscape Insights has been offering healthcare consulting services to these players with an aim to enhance their understanding on chronic disorders. It boasts a comprehensive portfolio of chronic disease research documents, encompassing a wide spectrum of ailments such as anemia, diabetes, stroke, obesity, arthritis, heart diseases, and more. Within DLI's extensive repository, these documents serve as a valuable resource, providing deep dive insights into the complexities of chronic ailments. Through DLI's advanced platform, chronic disease market players and stakeholders gain access to a wealth of knowledge that empowers them to make well-informed decisions.

Chronic Diseases- Characteristics, Symptoms and Implications

A significant portion of the world population is living with chronic disease. The characteristics and traits of these ailments are distinct. But most of these diseases are long lasting, highly complexed, non-transmissible, and progressive. Apart from that, some of the common symptoms triggered by all chronic ailments are fatigue, sudden weight fluctuation, frequent infections, and digestive issues, among others.

The proper identification of these symptoms is crucial for healthcare professionals to diagnose the potential ailment. It is worth noting that most incurable disease including chronic ones can be regulated with proper medical intervention. DLI has been assisting players in their chronic disease assessment so that they can expedite their therapy or drug development process.

Elucidating the treatment scenario

Chronic disease treatment vertical is vast, encompassing drugs, therapies, surgical interventions, and lifestyle changes, among others. Medication adherence in chronic disease is crucial because of its progressive nature. The prescribed medicines are required to be consumed by patients to manage the symptoms and slow down the disease progress. The chronic disease management market has been gaining massive traction over the years. This is due to the increased health cognizance of the masses along with the elevating demand for highly effective treatment solutions.

Price and Market Access

Here is an overview of the chronic disease management outlook- 

Lifestyle Modifications: Encouraging patients to adopt a healthy diet, exercise regularly, manage stress, and avoid smoking and excessive alcohol consumption is a common approach for many chronic diseases.

Medications: Depending on the specific chronic disease, medications may include antibiotics for chronic infections, antihypertensive drugs for high blood pressure, insulin or oral medications for diabetes, or anti-inflammatory drugs for conditions like arthritis.

Physical Therapy: Physical therapy can help manage chronic pain and improve mobility and function in conditions like osteoarthritis or chronic back pain.

Dietary Management: Dietary changes are often recommended to control chronic diseases, such as reducing sodium intake for hypertension, following a low-sugar diet for diabetes, or a low-fat diet for heart disease.

Regular Monitoring: Routine monitoring of vital signs, blood glucose levels, or other relevant markers is crucial for managing many chronic diseases.

Supportive Care: Supportive care, including palliative care and symptom management, may be necessary for advanced chronic conditions, such as cancer.

Medication Adherence: Ensuring that patients adhere to their prescribed medication regimens is vital for managing chronic diseases effectively.

Education: Providing patients with information about their condition, its management, and potential complications is essential for empowering them to take control of their health.

Surgery: In some cases, surgical interventions, such as joint replacement for osteoarthritis or coronary artery bypass surgery for advanced heart disease, may be necessary.

Mental Health Support: Managing the psychological aspects of living with a chronic disease often involves counseling or therapy to address depression, anxiety, or stress.

It is worth mentioning that the treatment plans may completely vary based on the disease type, overall health status of the patients, along with other physiological and psychological aspects.

DLI's Extended Role in Clinical Trial Assessment

Chronic disease epidemiology study extensively conducted by DLI suggests highlight the importance of early detection and screening which in turn paves the way for real time medical intervention. It is worth noting that medical researchers and chronic disease pharmacies/pharma leaders are working efficiently to develop favourable chronic disease products that can enhance the quality of life of the patients.

But in order to get these potential products including drugs and therapies approved for commercial use, they are required to undergo a strenuous chronic disease clinical trials process.  DLI has been a constant support for these players during this phase. Clinical trials are a complicated process wherein the participants are required to take care of multiple things simultaneously. Any sort of negligence may hinder the entire process.  DLI through its expertise in this domain has been involved in safety monitoring, data analysis, efficacy assessment, data review, participant protection, and chronic disease regulatory compliance. By offering these services, it has helped the players ensure the real time and successful completion of the clinical trial rounds.

Post successful trials, the next step for players is to launch their products. DLI equips them with in depth product launch services and drug launch strategies, enabling them to gain market access while strengthening their market position.

Post Launch Scenario

After the drug or therapy gets approval for commercial use and is launched in the market, the players starting formulating strategies that can help their products to make huge profits. For that, they ensure if their products are showing promising results. They do so by gathering and analysing customer insights. Many players seek consulting services in their post launch phase. DLI has been successfully empowering these players with product portfolio analysis, commercial strategy analysis, pricing and reimbursement-based data, along with product portfolio extension tactics.

Final Words

The increased pervasiveness of chronic diseases is a cause of concern across numerous nations. This has pushed medical researchers and other healthcare professionals to formulate effective chronic disease management solutions. Given the complexed nature of long-term illness, navigating through this journey can be rigorous and time consuming for the players. By collaborating with Disease Landscape Insights, they are being able to expedite their R&D activities. DLI has always been focused on chronic disease medicine reimbursement, in-depth chronic disease analysis, Clinical Trial Feasibility Analysis, and the provision of valuable drug insights signifies a holistic and forward-looking strategy. These strategies aim towards alleviating economical burden for patients while ensuring the efficiency of clinical trials. DLI has joined hands with the chronic disease vertical leaders to redefine landscape of chronic disease management, offering a more comprehensive and patient-centric approach to tackling these challenging medical conditions.

About Disease Landscape: 

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to the healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  

Disease Landscape Insights LLP 
6th Floor, Sr No.207, Office A H 6070 Phase 1
Solitaire Business Hub, Viman Nagar 
Pune, Maharashtra, 411014 
Email: ajay@diseaselandscape.com  
Email: vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs  
Case Study: https://www.diseaselandscape.com/casestudies   
Pharma consulting Services 

Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.